Steven N. Feldman

Steven Feldman helps clients navigate a broad range of high-stakes litigation, with a focus on complex commercial disputes and challenging class actions. Mr. Feldman, who was named a "Rising Star" by Super Lawyers magazine in 2016 and 2017, uses his experience at all stages of litigation to develop creative and aggressive case strategies for his clients, with the goal of obtaining their desired result – whether it be a favorable settlement or winning at trial. Not only does this place his clients in the best position to prevail, it also avoids unnecessary disputes and minimizes discovery costs. Mr. Feldman's clients have included companies such as Allergan, Amgen, T-Mobile and BHP Billiton, as well as high-profile individuals such as Alec Baldwin and Bill Koch.

Mr. Feldman has deep experience in the courtroom: In addition to serving as a member of the trial team that won a $12 million punitive damages verdict and liability findings on all counts in favor of his client following a three-week federal jury trial in the Southern District of New York, he has argued and won significant motions for clients in state and federal courts in California and New York. Most recently, Mr. Feldman secured the decertification of a consumer class action on behalf of a leading manufacturer of natural health products and nutritional supplements, in a decision Law360 called one of the "Class Certification Rulings Every Litigator Needs to Know."

Prior to joining Hueston Hennigan at its inception, Mr. Feldman was an associate at Irell & Manella LLP in Los Angeles and at Davis Polk & Wardwell in New York City, where he focused on complex business litigation and white collar defense. Mr. Feldman also served as a law clerk to the Hon. Jacqueline H. Nguyen of the U.S. Court of Appeals for the Ninth Circuit and, while in law school, as an extern to the Hon. Charles R. Breyer of the U.S. District Court in San Francisco and to the Hon. Robert D. Sack of the U.S. Court of Appeals for the Second Circuit.

Mr. Feldman serves on the Association of Business Trial Lawyers' Young Leadership Board and moderates "The Insight Roundtable," a series he created and developed, featuring one-on-one interviews with leading jurists, lawyers and business executives. Recent interviewees have included the general counsels of Toyota, Levi Strauss & Co., Kleiner Perkins Caufield & Byers, and The Honest Company. Mr. Feldman also serves on the Board of Directors of the Harvard Law School Alumni Association of Southern California.

Commercial Litigation

Goldcrest Film Distribution v. Summit Entertainment: Won the dismissal of a multimillion-dollar contractual dispute over alleged deceptive accounting practices used to calculate profit participations for the "Twilight" movie saga, on behalf of Lionsgate subsidiary Summit Distribution LLC.

Koch v. Greenberg: Won an eight-figure punitive damages verdict and liability findings on all claims of fraud, deceptive business practices and false advertising following a highly publicized, three-week jury trial in New York federal court in a suit related to the defendant's sale of counterfeit fine wine to our client.

T-Mobile v. Huawei et al.: Representing T-Mobile in a trade secret theft and breach of contract suit against China's largest phone manufacturer, relating to T-Mobile's proprietary robotics technology.

Alec Baldwin v. Mary Boone et al: Representing actor Alec Baldwin in a lawsuit alleging he was defrauded into purchasing counterfeit art by one of New York City's most prominent art gallerists (see "Alec Baldwin Sues Art Gallery Over Counterfeit Painting" in Law360 and Page Six).

Mosier v. Center Street Lending LLC et al: Obtained favorable settlement in a significant fraudulent transfer action on behalf of our client, Center Street Lending, a leading private lender that provides asset-based financing.

Class Action Defense

Lambert v. Nutraceutical Corp: Won decertification of a consumer class action brought against our client, Nutraceutical Corp., a publicly traded, leading manufacturer of health and dietary supplements, in a case alleging that the one of its top-selling products violated California false advertising and unfair competition laws. After the court conditionally certified the class at an early stage of litigation based on numerous representations Plaintiffs made about what they would prove during discovery, we set forth an aggressive discovery plan designed to hold Plaintiffs' feet to the fire, and following the close of discovery, successfully moved to decertify the class and dismiss the lead plaintiff with prejudice. (See "Judge Decertifies Class That Sued Over Marketing of Product" in the Daily Journal).

Ruhnke v. Allergan: Representing Allergan in a putative consumer class action litigation seeking over $85 million in damages. The suit alleges that Allergan's leading skincare and cosmetics line is in violation of the Food Drug and Cosmetics Act, and that the product is being marketed in a way that violates false advertising and unfair competition laws.

Lopez v. Caskers LLC: Obtained the voluntary dismissal of a putative consumer class action alleging violations of California's Automatic Renewal Law, on behalf of Caskers LLC, the leading e-commerce company focusing on the curation and sale of craft spirits.

CEH v. U.S. International Trading Corp: Obtained the voluntary dismissal of a putative consumer class action alleging that our client violated false advertising laws by misleadingly labeling a consumer product as "organic."

In re Amgen Inc. Securities Litigation: Represented Amgen, the world's largest biopharmaceutical company, in a national securities fraud class action alleging misstatements and omissions related to several of Amgen's most important drugs.

CEH v. Nutraceutical Corp. et al: Representing Nutraceutical in an important appellate matter regarding the scope of plaintiffs' suits brought under California's Proposition 65.

Hammock v. Nutramarks, Inc. et al: Representing Nutramarks, Inc., in a putative national consumer class action litigation related to a leading line of homeopathic products.